EFFECTS ON MORTALITY AND MORBIDITY IN OVERWEIGHT/OBESE SUBJECTS: THE SIBUTRAMINE CARDIOVASCULAR OUTCOMES (SCOUT) TRIAL

Philip James; Ian D. Caterson; Walmir Coutinho; Nick Finer; Luc Van Gaal; Aldo Maggioni; Arya M. Sharma

doi:10.1016/s0735-1097(10)61327-7

Related publications

Article2010

Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects

W. P. T. James, Ian D. Caterson, Walmir Coutinho, Nick Finer, Luc F. Van Gaal, Aldo Maggioni, Christian Torp‐Pedersen, Arya M. Sharma, Gillian Shepherd, Richard A. Rode, Cheryl Renz

Article2011

Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial

Ian D. Caterson, Nick Finer, Walmir Coutinho, Luc F. Van Gaal, Aldo Maggioni, Christian Torp‐Pedersen, Arya M. Sharma, Udo F. Legler, G Shepherd, Richard A. Rode, Renee Perdok, Cheryl Renz, W. P. T. James

Article2014

Changes in body weight and pulse: outcome events in overweight and obese subjects with cardiovascular disease in the SCOUT trial

Radhika V. Seimon, D. Espinoza, Nick Finer, W. P. T. James, Udo F. Legler, Walmir Coutinho, Arya M. Sharma, L. Van Gaal, Aldo Maggioni, Arianne Sweeting, Christian Torp‐Pedersen, Val Gebski, Ian D. Caterson

Article2007

Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial

Christian Torp‐Pedersen, Ian D. Caterson, Walmir Coutinho, Nick Finer, Luc Van Gaal, Aldo Maggioni, Arya M. Sharma, Wygenia Brisco, Roger Deaton, Gillian Shepherd, Philip James

Letter2009

SCOUT Trial Reports on the Safety Profile of Sibutramine in Patients with Cardiovascular Diseases

Aldo Maggioni